Global Neurodegenerative Disorder Therapeutics Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2022 –2029 |
 Market Size (Base Year) |
USD 14.66 Billion |
 Market Size (Forecast Year) |
USD 22.79 Billion |
 CAGR |
% |
| Major Markets Players |
>全球神经退行性疾病治疗市场，按适应症（多发性硬化症、阿尔茨海默病、帕金森病、亨廷顿病等）、药物玻璃（免疫调节剂、干扰素、脱羧酶抑制剂、多巴胺激动剂等）、给药途径（口服、注射、透皮）、最终用户（医院药房、零售药房、网上药房）划分——行业趋势和预测到 2029 年。
神经退行性疾病治疗市场分析和规模
《世界人口展望》预测，到 2050 年，60 岁以上的人口将达到 21 亿，80 岁以上的人口数量将增加两倍，达到 4.25 亿。根据阿尔茨海默病协会的数据，目前有 580 万美国人患有阿尔茨海默病，到 2050 年，这一数字预计将达到 1400 万。由于老龄化人口中神经退行性疾病的发病率不断上升，对神经退行性疾病治疗的需求不断增长，推动了市场的发展。
Data Bridge Market Research 分析认为，神经退行性疾病治疗市场在 2021 年为 146.6 亿美元，到 2029 年将飙升至 227.9 亿美元，预计在 2022 年至 2029 年的预测期内复合年增长率为 5.67%。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外，Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、管道分析、定价分析和监管框架。
神经退行性疾病治疗市场范围和细分
|
报告指标 |
细节 |
|
预测期 |
2022 至 2029 年 |
|
基准年 |
2021 |
|
历史岁月 |
2020（可定制为 2014 - 2019） |
|
定量单位 |
收入（单位：十亿美元）、销量（单位：台）、定价（美元） |
|
涵盖的领域 |
适应症（多发性硬化症、阿尔茨海默病、帕金森病、亨廷顿病等）、药物玻璃（免疫调节剂、干扰素、脱羧酶抑制剂、多巴胺激动剂等）、给药途径（口服、注射、透皮）、最终用户（医院药房、零售药房、网上药房） |
|
覆盖国家 |
北美洲的美国、加拿大和墨西哥、德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列、中东和非洲 (MEA) 的其他地区、巴西、阿根廷和南美洲其他地区 |
|
涵盖的市场参与者 |
Biogen (U.S.), Merck Sharp & Dohme Corp (U.S.), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Orion Corporation (Finland), UCB S.A. (Belgium), ACADIA Pharmaceuticals Inc. (U.S.), Mitsubishi Chemical Group Corporation (Japan), H. Lundbeck A/S (Denmark), Denali Therapeutics (U.S.), Aquinnah Pharmaceuticals (Japan), Prevail Therapeutics (U.S.), AZTherapies, Inc. (U.S.) |
|
Market Opportunities |
|
Market Definition
A variety of fatal diseases known as "neurodegenerative disorders" predominantly affect the neurons in the human brain and cause the progressive degeneration or death of nerve cells. The field of therapeutics for neurodegenerative disorders focuses on the production and research of medications and treatments that halt or reduce the neurodegenerative processes of illnesses including Parkinson's, Alzheimer's, Huntington's, and other neurodegenerative disorders.
Neurodegenerative Disorder Therapeutics Market Dynamics
Drivers
- Rise in prevalence of neurodegenerative diseases
Increased financing for neurodegenerative disease research is anticipated to boost market expansion. The market for neurodegenerative disorder therapeutics is expected to grow rapidly from 2022 to 2029 as a result of a number of additional factors, including an increase in the prevalence of neurodegenerative diseases, an ageing population, a rise in the risk of neurological disorders like Alzheimer's and Parkinson's disease, and a better understanding of the genetic foundations and molecular pathology of neurodegenerative diseases.
- Increase in elderly population
The market for therapies for neurodegenerative disorders is expanding as the prevalence of these diseases among the world's population rises. The rise in the population of elderly people is attributed to the rise in neurodegenerative illnesses.
Opportunities
The development of novel therapies for neurodegenerative disorders through gene and cell therapies and the massive scope for adoption of neurodegenerative disorders therapeutics in emerging nations will act as opportunities for market growth.
Restraints/Challenges
On the other hand, increasing failure rate of neurodegenerative drugs in clinical trials will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the market.
This neurodegenerative disorder therapeutics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the neurodegenerative disorder therapeutics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Neurodegenerative Disorder Therapeutics Market
The COVID-19 impact on the market was considerable since the pandemic affected clinical trial procedures, R&D operations, and pipeline products. As a result, growth during the pandemic was rather moderate despite the existence of a strong late-stage product pipeline. For instance, due to the difficulty of data processing and the effect of COVID-19 on its research and development studies, Biogen postponed the submission of its Alzheimer's medication application to the Food and Drug Administration. As a result of the aforementioned variables, the market under study saw a temporary slowdown in growth during the COVID-19 pandemic.
Recent Development
- In January 2020, Biogen Inc., an America Biotechnology company acquired a novel clinical stage asset, PF-05251749 along with the applications from Pfizer for $75 million.
Global Neurodegenerative Disorder Therapeutics Market Scope
The neurodegenerative disorder therapeutics market is segmented on the basis of indication, drug glass, route of administration and end- user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Indication
- Multiple sclerosis
- Alzheimer’s Disease
- Parkinson’s Disease
- Huntington’s Disease
- Others
Drug Glass
- Immunomodulator
- Interferons
- Decarboxylase Inhibitors
- Dopamine Agonists
- Others
Route of Administration
- Oral
- Injection
- Transdermal
End- User
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Neurodegenerative Disorder Therapeutics Market Regional Analysis/Insights
The neurodegenerative disorder therapeutics market is analysed and market size insights and trends are provided by country, indication, drug glass, route of administration and end- user as referenced above.
神经退行性疾病治疗市场报告涵盖的国家包括北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区 (APAC) 的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、中东和非洲 (MEA) 的其他地区、南美洲的巴西、阿根廷和南美洲其他地区。
由于北美对神经退行性疾病的认识不断提高，北美在神经退行性疾病治疗市场中占据主导地位。
由于健康意识的增强，预计亚太地区将在 2022 年至 2029 年的预测期内以最高的增长率增长。
报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。
竞争格局和神经退行性疾病治疗市场份额分析
神经退行性疾病治疗市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对神经退行性疾病治疗市场的关注有关。
神经退行性疾病治疗市场的一些主要参与者包括：
- Biogen（美国）
- 默克夏普和多姆公司 (美国)
- 诺华公司（瑞士）
- Teva Pharmaceutical Industries Ltd.（以色列）
- Orion 公司 (芬兰)
- UCB SA（比利时）
- ACADIA Pharmaceuticals Inc.（美国）
- 三菱化学集团公司（日本）
- H. Lundbeck A/S（丹麦）
- Denali Therapeutics（美国）
- Aquinnah Pharmaceuticals（日本）
- Prevail Therapeutics（美国）
- AZTherapies, Inc.（美国）
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
